Search

Your search keyword '"Lekakis, J."' showing total 4 results
Start Over Author "Lekakis, J." Topic coronary artery disease
4 results on '"Lekakis, J."'

1. Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology

Author

Patrono, C, Bachmann, F, Baigent, C, Bode, C, De Caterina, R, Charbonnier, B, Fitzgerald, D, Hirsh, J, Husted, S, Kvasnicka, J, Montalescot, G, García Rodríguez, LA, Verheugt, F, Vermylen, J, Wallentin, L, Priori, SG, Alonso Garcia, MA, Blanc, JJ, Budaj, A, Cowie, M, Dean, V, Deckers, J, Fernández Burgos, E, Lekakis, J, Lindahl, B, Mazzotta, G, Morais, J, Oto, A, Smiseth, OA, Ferreira, R, Steg, PG, Teixeira, F, Wilcox, R, and Cardiology

Subjects
Blood Platelets, medicine.medical_specialty, Process (engineering), media_common.quotation_subject, Alternative medicine, Coronary Artery Disease, Risk Assessment, Task (project management), SDG 3 - Good Health and Well-being, Risk Factors, Internal medicine, medicine, Humans, In patient, Quality (business), Heart, lung and circulation [UMCN 2.1], media_common, Clinical Trials as Topic, Atherosclerotic cardiovascular disease, business.industry, Patient Selection, Expert consensus, Clinical trial, Cardiology, Cardiology and Cardiovascular Medicine, business, Platelet Aggregation Inhibitors
Abstract

Guidelines and Expert Consensus Documents aim to present all the relevant evidence on a particular issue in order to help physicians to weigh the benefits and risks of a particular diagnostic or therapeutic procedure. They should be helpful in everyday clinical decision-making. A great number of Guidelines and Expert Consensus Documents have been issued in recent years by different organizations, the European Society of Cardiology (ESC) and by other related societies. By means of links to web sites of National Societies several hundred guidelines are available. This profusion can put at stake the authority and validity of guidelines, which can only be guaranteed if they have been developed by an unquestionable decision-making process. This is one of the reasons why the ESC and others have issued recommendations for formulating and issuing Guidelines and Expert Consensus Documents. In spite of the fact that standards for issuing good quality Guidelines and Expert Consensus Documents are well defined, recent surveys of Guidelines and Expert Consensus Documents published in peer-reviewed journals between 1985 and 1998 have shown that methodological standards were not complied within the vast majority of cases. It is therefore of great importance that guidelines and recommendations are presented in formats that are easily interpreted. Subsequently, their implementation programmes must also be well conducted. Attempts have been made to determine whether guidelines improve the quality of clinical practice and the utilization of health resources. The ESC Committee for Practice Guidelines ( CPG ) supervises and coordinates the preparation of new Guidelines and Expert Consensus Documents produced by Task Forces, expert groups or consensus panels. The Committee is also responsible for the endorsement of these Guidelines and Expert Consensus Documents or statements. The role of aspirin and other platelet-active drugs in the treatment and prevention of atherothrombosis has been reviewed recently by the Sixth American …

Published
2016

2. ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)

Author

Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E, Chapman MJ, Durrington P, Erdine S, Halcox J, Hobbs R, Kjekshus J, Storey RF, Wood D, ESC Committee for Practice Guidelines 2008–2010, 2010–2012 Committees, Bax J, Vahanian A, Auricchio A, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Filippatos G, Funck Brentano C, Hasdai D, Hoes A, Kearney P, Knuuti J, Kolh P, McDonagh T, Moulin C, Poldermans D, Popescu BA, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vardas P, Widimsky P, Windecker S, Document Reviewers, Berkenboom G, De Graaf J, Descamps O, Gotcheva N, Griffith K, Guida GF, Gulec S, Henkin Y, Huber K, Kesaniemi YA, Lekakis J, Manolis AJ, Marques Vidal P, Masana L, McMurray J, Mendes M, Pagava Z, Pedersen T, Prescott E, Rato Q, Rosano G, Sans S, Stalenhoef A, Tokgozoglu L, Viigimaa M, Wittekoek ME, Zamorano J.L., PERRONE FILARDI, PASQUALE, RICCARDI, GABRIELE, Reiner, Z, Catapano, Al, De Backer, G, Graham, I, Taskinen, Mr, Wiklund, O, Agewall, S, Alegria, E, Chapman, Mj, Durrington, P, Erdine, S, Halcox, J, Hobbs, R, Kjekshus, J, PERRONE FILARDI, Pasquale, Riccardi, Gabriele, Storey, Rf, Wood, D, ESC Committee for Practice Guidelines, 2008–2010, 2010–2012, Committee, Bax, J, Vahanian, A, Auricchio, A, Baumgartner, H, Ceconi, C, Dean, V, Deaton, C, Fagard, R, Filippatos, G, Funck Brentano, C, Hasdai, D, Hoes, A, Kearney, P, Knuuti, J, Kolh, P, Mcdonagh, T, Moulin, C, Poldermans, D, Popescu, Ba, Sechtem, U, Sirnes, Pa, Tendera, M, Torbicki, A, Vardas, P, Widimsky, P, Windecker, S, Document, Reviewers, Berkenboom, G, De Graaf, J, Descamps, O, Gotcheva, N, Griffith, K, Guida, Gf, Gulec, S, Henkin, Y, Huber, K, Kesaniemi, Ya, Lekakis, J, Manolis, Aj, Marques Vidal, P, Masana, L, Mcmurray, J, Mendes, M, Pagava, Z, Pedersen, T, Prescott, E, Rato, Q, Rosano, G, Sans, S, Stalenhoef, A, Tokgozoglu, L, Viigimaa, M, Wittekoek, Me, Zamorano, J. L., Alberico L., Catapano, Željko, Reiner, Guy De, Backer, Ian, Graham, Marja Riitta, Taskinen, Olov, Wiklund, Stefan, Agewall, Eduardo, Alegria, M., John Chapman, Paul, Durrington, Serap, Erdine, Julian, Halcox, Richard, Hobb, John, Kjekshu, Robert F., Storey, and David, Wood

Subjects
Male, Nice, Type 2 diabetes, Disease, Coronary artery disease, Risk Factors, Health care, Secondary Prevention, Child, Societies, Medical, media_common, computer.programming_language, Hypolipidemic Agents, Clinical Trials as Topic, Middle Aged, Lipids, Europe, Primary Prevention, Cholesterol, Cardiovascular Diseases, Practice Guidelines as Topic, Female, Cardiology and Cardiovascular Medicine, Risk assessment, Risk, Adult, medicine.medical_specialty, Adolescent, Genotype, Lipoproteins, Advisory Committees, Cardiology, Guidelines as Topic, Risk Assessment, Specimen Handling, Sex Factors, Internal medicine, Weight Loss, medicine, media_common.cataloged_instance, Humans, cardiovascular diseases, European union, Intensive care medicine, Exercise, Life Style, Health aging / healthy living Cardiovascular diseases [IGMD 5], Aged, Dyslipidemias, Transplantation, business.industry, Guideline, medicine.disease, Atherosclerosis, Lipid Metabolism, Dietary Fats, Diet, Endocrinology, Early Diagnosis, Dietary Supplements, Kidney Failure, Chronic, Patient Compliance, business, Energy Intake, computer, Lipoprotein(a)
Abstract

Item does not contain fulltext Cardiovascular disease (CVD) due to atherosclerosis of the arterial vessel wall and to thrombosis is the foremost cause of premature mortality and of disability-adjusted life years (DALYs) in Europe, and is also increasingly common in developing countries.1 In the European Union, the economic cost of CVD represents annually E192 billion1 in direct and indirect healthcare costs. The main clinical entities are coronary artery disease (CAD), ischaemic stroke, and peripheral arterial disease (PAD). The causes of these CVDs are multifactorial. Some of these factors relate to lifestyles, such as tobacco smoking, lack of physical activity, and dietary habits, and are thus modifiable. Other risk factors are also modifiable, such as elevated blood pressure, type 2 diabetes, and dyslipidaemias, or non-modifiable, such as age and male gender. These guidelines deal with the management of dyslipidaemias as an essential and integral part of CVD prevention. Prevention and treatment of dyslipidaemias should always be considered within the broader framework of CVD prevention, which is addressed in guidelines of the Joint European Societies' Task forces on CVD prevention in clinical practice.2 - 5 The latest version of these guidelines was published in 20075; an update will become available in 2012. These Joint ESC/European Atherosclerosis Society (EAS) guidelines on the management of dyslipidaemias are complementary to the guidelines on CVD prevention in clinical practice and address not only physicians [e.g. general practitioners (GPs) and cardiologists] interested in CVD prevention, but also specialists from lipid clinics or metabolic units who are dealing with dyslipidaemias that are more difficult to classify and treat.

Published
2011

3. Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology

Author

Fox K, Garcia MA, Ardissino D, Buszman P, CAMICI , PAOLO, Crea F, Daly C, De Backer G, Hjemdahl P, Lopez Sendon J, Marco J, Morais J, Pepper J, Sechtem U, Simoons M, Thygesen K, Priori SG, Blanc JJ, Budaj A, Camm J, Dean V, Deckers J, Dickstein K, Lekakis J, McGregor K, Metra M, Osterspey A, Tamargo J, Zamorano JL, Andreotti F, Becher H, Dietz R, Fraser A, Gray H, Antolin RA, Huber K, Kremastinos DT, Maseri A, Nesser HJ, Pasierski T, Sigwart U, Tubaro M, Weis M., Fox, K, Garcia, Ma, Ardissino, D, Buszman, P, Camici, Paolo, Crea, F, Daly, C, De Backer, G, Hjemdahl, P, Lopez Sendon, J, Marco, J, Morais, J, Pepper, J, Sechtem, U, Simoons, M, Thygesen, K, Priori, Sg, Blanc, Jj, Budaj, A, Camm, J, Dean, V, Deckers, J, Dickstein, K, Lekakis, J, Mcgregor, K, Metra, M, Osterspey, A, Tamargo, J, Zamorano, Jl, Andreotti, F, Becher, H, Dietz, R, Fraser, A, Gray, H, Antolin, Ra, Huber, K, Kremastinos, Dt, Maseri, A, Nesser, Hj, Pasierski, T, Sigwart, U, Tubaro, M, and Weis, M.

Subjects
Male, medicine.medical_specialty, Cardiotonic Agents, medicine.medical_treatment, Placebo-controlled study, Revascularization, Coronary Angiography, Risk Assessment, law.invention, Angina Pectoris, Coronary artery disease, Electrocardiography, Pharmacotherapy, Randomized controlled trial, law, Diabetes mellitus, Internal medicine, medicine, Myocardial Revascularization, Humans, Myocardial infarction, Angioplasty, Balloon, Coronary, Coronary Artery Bypass, Medical History Taking, Referral and Consultation, Aged, Executive summary, business.industry, Clinical Laboratory Techniques, Middle Aged, medicine.disease, Cardiology, Exercise Test, Female, Stents, Cardiology and Cardiovascular Medicine, business
Abstract

Under the heading ‘Hypertension, diabetes, and other disorders’ on page 1358, the guidelines1 lean on the taskforce report on CVD prevention2 suggesting ‘considering a lower threshold for institution of pharmacological therapy for hypertension (130/85) for patients with established coronary heart disease (which would include patients with …

Published
2006

4. Aspirin reduces anticardiolipin antibodies in patients with coronary artery disease.

Author

Ikonomidis, I., Lekakis, J., Vamvakou, G., Loizou, S., Revela, I., Andreotti, F., Kremastinos, D. Th., and Nihoyannopoulos, P.

Subjects
*CARDIOLIPIN, *ASPIRIN, *CORONARY disease, *INFLAMMATION, *C-reactive protein, *IMMUNOGLOBULINS
Abstract

Background Anticardiolipin antibodies (aCL) have been found to be elevated in patients with coronary artery disease (CAD) and have been associated with an adverse outcome owing to their prothrombotic activity. The aim of this study was to investigate the effect of aspirin treatment on aCL levels in patients with chronic CAD. Materials and methods Forty patients with chronic CAD scheduled for elective coronary artery bypass graft surgery (CABG) and 40 healthy controls participated in the study. Patients were treated with 300 mg of aspirin once daily (o.d.) for the first 12 days and placebo for the following 12 days before CABG in a double-blind, cross-over trial. Immunoglobulin (Ig) G-, IgM-, IgA-aCL and C-reactive protein (CRP) levels were measured in the controls and at the end of each treatment period in the patients with CAD. Results The IgA- and IgG-aCL levels were greater in patients with CAD than in the controls. Compared with the placebo, IgA, IgG subtypes and CRP levels were reduced after aspirin treatment ( P = 0·001, P = 0·02, P = 0·04, respectively). The percentage reduction of IgA- and IgG-aCL was related to the percentage reduction of CRP after aspirin ( P < 0·05). Conclusion Aspirin treatment with 300 mg o.d. reduced the serum levels of IgA and IgG subtypes in patients with chronic CAD in parallel to a reduction in CRP. These findings offer an additional pathophysiological mechanism of the beneficial effects of aspirin in patients with chronic CAD. [ABSTRACT FROM AUTHOR]

Published
2006
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results